When Amazon Web Services redefined enterprise computing, it did so not by writing applications but by owning the infrastructure beneath them. NVIDIA appears to be executing a strikingly similar strategy across the global pharmaceutical industry — and BioNeMo is its platform of record.
Over the past year, BioNeMo has quietly become the default AI infrastructure layer for a growing cohort of drug discovery and biotech organisations worldwide. The platform provides pre-trained biological foundation models, GPU-accelerated workflows, and APIs for molecular biology and genomics tasks. It is now embedded in the R&D pipelines of companies ranging from Big Pharma incumbents to venture-backed startups across North America, Europe, and beyond.
The strategic parallel to AWS is not merely rhetorical. Just as cloud infrastructure consolidated around a handful of American hyperscalers — reshaping enterprise IT in every country regardless of local preference — the pharmaceutical AI stack appears to be consolidating around NVIDIA's hardware and model infrastructure. The geopolitical and commercial implications of that consolidation are only beginning to be understood.
Anchor Partnerships Signal Platform Credibility
The clearest signal of BioNeMo's institutional traction is its adoption by Eli Lilly and Thermo Fisher Scientific — two organisations whose technology choices carry significant downstream influence across the global industry. Eli Lilly, which committed $2.5 billion to AI and digital capabilities between 2020 and 2024, is integrating BioNeMo's molecular simulation tools into its early-stage discovery workflows. Thermo Fisher, a critical instruments and services provider to virtually every major pharma company worldwide, represents a multiplier effect: BioNeMo capabilities embedded in Thermo Fisher's platforms reach clients who may never directly license NVIDIA software — including laboratories in emerging markets across Asia, Latin America, and Africa.
These partnerships are not merely commercial wins. They function as credibility signals that accelerate adoption across the broader global ecosystem, much as early AWS enterprise customers legitimised cloud computing for cautious multinationals in the 2010s.
A European and Global Ecosystem Takes Shape
The more structurally significant development is the proliferation of specialised AI biotech firms building foundation models atop BioNeMo's infrastructure — and notably, this trend is not confined to the United States. Apheris, a Berlin-based federated AI company, has trained proprietary models on BioNeMo, reflecting Europe's growing role in privacy-preserving biomedical AI. Owkin, the Franco-American biotech, operates a federated learning platform for clinical data that sits within the same architectural wave. Basecamp Research, a UK-based firm mining biodiversity data for novel proteins, further illustrates how BioNeMo is becoming a common substrate for geographically dispersed innovation.
Terray Therapeutics and Natera, both US-based, round out a picture of an ecosystem where firms on multiple continents are effectively betting that NVIDIA's platform will remain the dominant computational layer for biological AI. This is the classic platform lock-in dynamic: as more models, tools, and workflows are built atop BioNeMo, switching costs rise for the entire global ecosystem.
The Infrastructure Thesis and Its Global Stakes
What makes BioNeMo strategically distinct from a simple software toolkit is its positioning at the model layer rather than the application layer. By providing pre-trained foundation models for protein structure prediction, molecular docking, and genomic sequence analysis, NVIDIA is capturing value at the precise intersection of compute and biology — a position that grows more defensible as the models improve and the ecosystem deepens.
This has direct implications for countries and regions seeking to build sovereign pharmaceutical AI capacity. The European Union's push for digital sovereignty, China's state-backed investment in homegrown AI infrastructure, and India's nascent ambitions in computational biology all represent implicit responses to the risk of critical scientific infrastructure consolidating under a single American technology company. Whether those responses can produce viable alternatives remains an open question.
For now, the trajectory resembles the early years of cloud computing: a window in which the infrastructure choices of leading institutions are quietly determining the architecture of an entire industry — one that, in this case, is responsible for the medicines that reach patients around the world.
Sources:
1 Yahoo Finance, "NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery" (January 12, 2026)